{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:43:55Z","timestamp":1761237835199},"publisher-location":"Berlin, Heidelberg","reference-count":63,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642630705"},{"type":"electronic","value":"9783642571510"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000]]},"DOI":"10.1007\/978-3-642-57151-0_15","type":"book-chapter","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T06:58:51Z","timestamp":1315378731000},"page":"178-189","source":"Crossref","is-referenced-by-count":22,"title":["Adjuvant Therapy of Malignant Melanoma and the Role of Sentinel Node Mapping"],"prefix":"10.1007","author":[{"given":"A. M. M.","family":"Eggermont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"15_CR1","first-page":"387","volume":"12","author":"P Banzet","year":"1993","unstructured":"Banzet P, Thomas A, Vuillemin E, et al: Wide versus narrow surgical excision in thin %lt;2 mm) stage I primary cutaneous malignant melanoma: long term results of a french multicentric prospective randomized trial on 319 patients. Proc. Am. Assoc. Clin. Oncol. 12:387, 1993","journal-title":"Proc. Am. Assoc. Clin. Oncol."},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1809::AID-CNCR8>3.0.CO;2-6","volume":"77","author":"U Ringborg","year":"1996","unstructured":"Ringborg U, Andersson R, Eldh J, et al: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0mm: randomized study by the Swedish Melanoma Study Group. Cancer 77:1809\u20131814, 1996","journal-title":"Cancer"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJM198805053181804","volume":"318","author":"U Veronesi","year":"1988","unstructured":"Veronesi U, Cascinelli N, Adamus J, et al: Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 em [published erratum appear s in N Engl J Med 1991 Jul 25;325(4):292]. N Engl J Med 318:1159\u20131162, 1988","journal-title":"N Engl J Med"},{"key":"15_CR4","unstructured":"Cascinelli N: Update WHO-10 trial. WHO-program meeting, May 1995, Albany, NY, USA:317-321, 1995"},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00000658-199309000-00005","volume":"218","author":"CM Balch","year":"1993","unstructured":"Balch CM, Urist MM, Karakousis CP, et al: Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (l to 4 mm). Results of a multi-institutional randomized surgical trial [see comments]. Ann Surg 218:262\u2013267; discussion 267-269, 1993","journal-title":"Ann Surg"},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/BF02305762","volume":"3","author":"CP Karakousis","year":"1996","unstructured":"Karakousis CP, Balch CM, Urist MM, et al: Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 3:446\u2013452, 1996","journal-title":"Ann Surg Oncol"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/BF02303495","volume":"5","author":"KM Heaton","year":"1998","unstructured":"Heaton KM, Sussman JJ, Gershenwald JE, et al: Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 5:322\u2013328, 1998","journal-title":"Ann Surg Oncol"},{"key":"15_CR8","first-page":"335","volume":"26","author":"AMM Eggermont","year":"1996","unstructured":"Eggermont AMM. Treatment of melanoma in-transit metastasis confined to the limb. Cancer Surveys 1996; 26:335\u2013349","journal-title":"Cancer Surveys"},{"key":"15_CR9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.1988.6.4.701","volume":"6","author":"HR Franklin","year":"1988","unstructured":"Franklin HR, Schraffordt Koops H, Oldhoff J, et al: To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thicknes s of 1.5mm or greater. J Clin Oncol 6:701\u2013708, 1988","journal-title":"J Clin Oncol"},{"key":"15_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/00000658-198412000-00016","volume":"200","author":"F Ghussen","year":"1984","unstructured":"Ghussen F, Nagel K, Groth W, et al: A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 200:764\u2013768, 1984","journal-title":"Ann Surg"},{"key":"15_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0748-7983(97)80134-5","volume":"23","author":"NJ Fenn","year":"1997","unstructured":"Fenn NJ., Horgan K, Johnson RC., et al: A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb. Eur J Surg Oncol 23:6\u20139, 1997","journal-title":"Eur J Surg Oncol"},{"key":"15_CR12","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1200\/JCO.1998.16.9.2906","volume":"16","author":"HS Koops","year":"1998","unstructured":"Schraffordt Koops H, Vaglini M, Suciu S, et al: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 16:2906\u20132912, 1998","journal-title":"J Clin Oncol"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/00000658-198212001-00011","volume":"196","author":"CM Balch","year":"1982","unstructured":"Balch CM, Soong S-J, Milton GW, Shaw HM, McGovern VJ, Murad TM, McCarthy WH, Maddox WA. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama USA, and New South Wales. Australia Ann Surg 1982; 196: 677","journal-title":"Australia Ann Surg"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/bjs.1800690217","volume":"69","author":"GW Milton","year":"1982","unstructured":"Milton GW, Shaw HM, McCarthy WH, Pearson L, Balch CM, Soong S-J. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982; 69:108","journal-title":"Br J Surg"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00000658-198309000-00014","volume":"198","author":"DS Reintgen","year":"1983","unstructured":"Reintgen DS., Cox EB, McCarthy KS Jr, Vollmer RT, Seigler HE Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198:379","journal-title":"Ann Surg"},{"key":"15_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/1097-0142(19930801)72:3<741::AID-CNCR2820720318>3.0.CO;2-W","volume":"72","author":"H Drepper","year":"1993","unstructured":"Drepper H., Kohler CO, Bastian B, et al: Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients. Cancer 72:741\u201374, 1993","journal-title":"Cancer"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/00000658-199402000-00003","volume":"219","author":"CL Slingluff Jr.","year":"1994","unstructured":"Slingluff CL., Jr., Stidham KR, Ricci WR, et al: Surgical management of regional lymph nodes in patients with melanoma. Ann Surg 219:120\u2013130, 1994","journal-title":"Ann Surg"},{"key":"15_CR18","first-page":"402","volume":"180","author":"AS Coates","year":"1995","unstructured":"Coates AS, Ingvar CI, Petersen-Schaefer K, et al: Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991 [see comments]. J Am Coli Surg 180:402\u2013409, 1995","journal-title":"J Am Coli Surg"},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1056\/NEJM197709222971202","volume":"297","author":"U Veronesi","year":"1977","unstructured":"Veronesi U, Adamus J, Bandiera DC, et al: Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 297:627\u2013630, 1977","journal-title":"N Engl J Med"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2","volume":"49","author":"U Veronesi","year":"1982","unstructured":"Veronesi U: Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49:2420\u20132430, 1982","journal-title":"Cancer"},{"key":"15_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/1097-0142(197803)41:3<948::AID-CNCR2820410324>3.0.CO;2-Z","volume":"41","author":"FH Sim","year":"1985","unstructured":"Sim FH.: A prospective randomized study of the efficacy of routine elective lymphadenopathy in management of malignant melanoma; preliminary results. Cancer 41:948\u2013951, 1985","journal-title":"Cancer"},{"key":"15_CR22","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0025-6196(12)62768-2","volume":"61","author":"FH Sim","year":"1986","unstructured":"Sim FH.: Lymphadenectomy in the management of stage 1 malignant melanoma: a prospective randomized study. Mayo Clin Proc 61:697\u2013705, 1986","journal-title":"Mayo Clin Proc"},{"key":"15_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00000658-199609000-00002","volume":"224","author":"CM Balch","year":"1996","unstructured":"Balch CM., Soong SJ., Bartolucci AA., et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255\u2013263; discussion 263-266, 1996","journal-title":"Ann Surg"},{"key":"15_CR24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","volume":"127","author":"DL Morton","year":"1992","unstructured":"Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surgery 1992; 127:392-399","journal-title":"Arch Surgery"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00000658-199602000-00016","volume":"223","author":"JJ Albertini","year":"1996","unstructured":"Albertini JJ, Cruse W, Berman C, et al. Intraoperative radiolymphoscintigraphy impoves sentinel lymph node identification for patients with melanoma. Ann Surg, 1996; 223:217\u2013224","journal-title":"Ann Surg"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00008390-199508000-00008","volume":"5","author":"JF Thompson","year":"1995","unstructured":"Thompson JF, McCarthy WH, Bosch CMJ, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res, 1995; 5:255\u2013260","journal-title":"Melanoma Res"},{"key":"15_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0039-6060(98)70121-7","volume":"124","author":"JE Gershenwald","year":"1998","unstructured":"Gershenwald JE., Tscheng C-h, Thompson W, et al. Improved sentinel lymph node localization in primary melanoma patients with the use of radiolabeled colloid. Surgery, 1998; 124:203\u2013210","journal-title":"Surgery"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/archsurg.1995.01430060092018","volume":"130","author":"DN Krag","year":"1995","unstructured":"Krag DN., Meijer SL., Weaver DL., et al. Minimal-access surgery for staging of melanoma. Arch Surg 1995; 130:654\u2013658","journal-title":"Arch Surg"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/00008390-199412000-00009","volume":"4","author":"RF Uren","year":"1994","unstructured":"Uren RF, Howman-Giles R, Thompson JF, et al. Lymphoscintigraphy to identify sentinel lymph nodes in patients with melanoma. Melanoma Res, 1994;4:395\u2013399","journal-title":"Melanoma Res"},{"key":"15_CR30","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.1998.16.6.2253","volume":"16","author":"JE Gershenwald","year":"1998","unstructured":"Gershenwald JE., Colomi MI, Thompson W, Mansfield PE, Lee JE., Colome MI, Tcheng C-h, Balch CM, Reintgen DS, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol, 1998; 16:2253\u20132260","journal-title":"J Clin Oncol"},{"key":"15_CR31","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1999.17.3.976","volume":"17","author":"JE Gershenwald","year":"1999","unstructured":"Gershenwald JE., Thompson W, Mansfield PE., Lee JE., Colome MI., Tcheng C-h., Balch CM., Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: value of sentinel lymph node status in 612 stage I or stage II melanoma patients. J Clin Oncol, 1999; 17:976\u2013983","journal-title":"J Clin Oncol"},{"issue":"16","key":"15_CR32","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/jama.280.16.1410","volume":"28","author":"SC Shivers","year":"1998","unstructured":"Shivers SC., Wang X, Li W, Joseph E, Messina J, Glass LF., DeConti R, Cruse CW, Berman C, Fenske NA, Lyman GH, Reintgen DS. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 28(16)1410\u20131415","journal-title":"JAMA"},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1002\/1097-0142(19810601)47:11<2556::AID-CNCR2820471107>3.0.CO;2-J","volume":"47","author":"GJ Hill II","year":"1981","unstructured":"Hill GJ. II, Moss SE., Golomb FM..., et al. DTIC and combination therapy for melanoma. Cancer 1981; 47:2556\u20132562","journal-title":"Cancer"},{"key":"15_CR34","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0039-6109(16)42581-8","volume":"61","author":"CM Pinsky","year":"1981","unstructured":"Pinsky CM., Oettgen HF.: Surgical adjuvant for malignant melanoma. Surg Clin North Am 1981; 61:1259\u20131266","journal-title":"Surg Clin North Am"},{"key":"15_CR35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJM198210073071503","volume":"307","author":"U Veronesi","year":"1982","unstructured":"Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307:913\u2013916","journal-title":"N Engl J Med"},{"key":"15_CR36","first-page":"929","volume":"128","author":"IC Quirt","year":"1983","unstructured":"Quirt IC., DeBoer G, Kersey PA, et al. Randomized controlled trial of adjuvant chernoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J 1983; 128:929\u2013936","journal-title":"Can Med Assoc J"},{"key":"15_CR37","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0039-6109(16)42582-X","volume":"61","author":"RI Fisher","year":"1981","unstructured":"Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma: Preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am 1981; 61:1267\u20131277","journal-title":"Surg Clin North Am"},{"key":"15_CR38","first-page":"325","volume":"10","author":"A Loutfi","year":"1987","unstructured":"Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole\/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987; 10:325\u2013328","journal-title":"Clin Invest Med"},{"key":"15_CR39","first-page":"643","volume":"71","author":"BL Tranum","year":"1987","unstructured":"Tranum BL, Dixon D, Quagliana J, et al. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep 1987; 71:643\u2013644","journal-title":"Cancer Treat Rep"},{"key":"15_CR40","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0959-8049(93)90064-M","volume":"29A","author":"BM Czarnetzki","year":"1993","unstructured":"Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, R\u00fcmke Ph. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatement in a randomised multicentre study (EORTC PROTOCOL 18781). Eur J Cancer 1993; 29A:1237\u20131242","journal-title":"Eur J Cancer"},{"key":"15_CR41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/0277-5379(88)90197-6","volume":"24","author":"FJ Lejeune","year":"1988","unstructured":"Lejeune FJ, Macher E, Kleeberg UR... et al. An Assessment of DTIC versus Levamisol and placebo in the treatment of high risk stage I patients after removal of a primary melanoma of the skin, A phase III adjuvant study. EORTC PROTOCOL 18761. Eur J Cancer Clin Oncol, 1988; 24:881\u2013890","journal-title":"Eur J Cancer Clin Oncol"},{"key":"15_CR42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.1991.9.5.729","volume":"9","author":"IC Quirt","year":"1991","unstructured":"Quirt IC, Shelley WE, Pater JL. et al. Improved survival in patients with poor prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the national cancer institute of Canada clinical trials group. J Clin Oncol 1991; 9:729\u2013735","journal-title":"J Clin Oncol"},{"key":"15_CR43","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.1991.9.5.736","volume":"9","author":"LE Spitler","year":"1991","unstructured":"Spitler LE... A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991; 9:736\u2013740","journal-title":"J Clin Oncol"},{"key":"15_CR44","first-page":"1739","volume":"63","author":"CP Karakousis","year":"1979","unstructured":"Karakousis CP, Didolkar MS, Lopez R..., et al. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma. Cancer Treat Rep 1979; 63:1739\u20131743","journal-title":"Cancer Treat Rep"},{"key":"15_CR45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/1097-0142(19820315)49:6<1079::AID-CNCR2820490604>3.0.CO;2-X","volume":"49","author":"CM Balch","year":"1982","unstructured":"Balch CM, Smalley RV, Bartolucci AA... et al. A randomized prospective trial of adjuvant C. Parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): progrnostic factors analysis and preliminary results of immnotherapy. Cancer 1982:49:1079\u20131084","journal-title":"Cancer"},{"key":"15_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/bjs.1800730211","volume":"73","author":"N Thatcher","year":"1986","unstructured":"Thatcher N, Mene A, Banerjee SS..., et al. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma. Br J Surg 1986; 73:111\u2013115","journal-title":"Br J Surg"},{"key":"15_CR47","unstructured":"Morton DL, Holmes EC, Eilber FR..., et al. Adjuvant immunotherapy: Results of a randomized trial in patients with lymph node metastases, in Terry WD, Rosenberg SA... (eds): Immunotherapy of Human Cancer. New York, NY, Elsevier North Holland, 1982, pp 245\u2013249"},{"key":"15_CR48","unstructured":"Terry WD, Hodes RJ, Rosenberg SA..., et al. Treatment of stage I and II malignant melanoma with adjuvant immunotherapy or chemotherapy: Preliminary analysis of a prospective randomized trial, in Terry WD, Rosenberg SA (eds): Immunotherapy of Human Cancer. New York, NY, Elsevier North Holland, 1982, pp 252\u2013257"},{"key":"15_CR49","first-page":"31","volume":"2","author":"DL Morton","year":"1986","unstructured":"Morton DL. Adjuvant immunotherapy of malignant melanoma: Status of clinical trials at UCLA. Int J Immunother 1986; 2:31\u201336","journal-title":"Int J Immunother"},{"key":"15_CR50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/1097-0142(19950101)75:1<34::AID-CNCR2820750108>3.0.CO;2-0","volume":"75","author":"MK Wallack","year":"1995","unstructured":"Wallack MK, Sivanandham M, Balch CM..., et al. A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34\u201342","journal-title":"Cancer"},{"key":"15_CR51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/00008390-199704000-00042","volume":"7","author":"P Hersey","year":"1997","unstructured":"Hersey P, Coates P, Tyndall L. Is adjuvant therapy worthwhile? Melanoma Res 1997; 7(Suppl): (abstract) 78","journal-title":"Melanoma Res"},{"key":"15_CR52","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.1994.12.10.2060","volume":"12","author":"FL Meyskens","year":"1994","unstructured":"Meyskens FL, Liu PY, Tuthill RI..., et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Soutwest Oncology Group Study J Clin Oncol 1994; 12:2060\u20132065","journal-title":"J Clin Oncol"},{"key":"15_CR53","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/jnci\/87.22.1710","volume":"87","author":"FL Meyskens","year":"1995","unstructured":"Meyskens FL, Kopecky KI, Taylor CW et al. Randomized trial of adjuvant human Interferon-gamma versus observation in high risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl. Cancer Inst 1995;87:1710\u20131713","journal-title":"J Natl. Cancer Inst"},{"key":"15_CR54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00008390-199704000-00038","volume":"7","author":"A Hauschild","year":"1997","unstructured":"Hauschild A, Burg G, Dummer R. Prospective randomized multicenter trial on the oupatient use of subcutaneous interleukin 2 and interferon a 2b in high risk melanoma patients. Melanoma Res 1997; 7(Suppll):(abstract) 401","journal-title":"Melanoma Res"},{"key":"15_CR55","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1200\/JCO.1994.12.5.1036","volume":"12","author":"PO Livingstone","year":"1994","unstructured":"Livingstone PO, Wong GYC, Adluri S..., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036\u201344","journal-title":"J Clin Oncol"},{"issue":"S2","key":"15_CR56","first-page":"127","volume":"7","author":"AMM Eggemont","year":"1997","unstructured":"Eggemont AMM. The Current Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxiity and costs. Melanoma Research, 1997; 7(S2) 127\u2013131","journal-title":"Melanoma Research"},{"key":"15_CR57","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1998.16.4.1425","volume":"16","author":"H Pehamberger","year":"1998","unstructured":"Pehamberger H, Soyer P, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock I, Fritsch P, Kerl H, Wolff K. Adjuvant interferon a-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol, 1998; 16:1425\u20131429","journal-title":"J Clin Oncol"},{"key":"15_CR58","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","volume":"351","author":"JJ Grob","year":"1998","unstructured":"Grob JJ, Dreno B, Chastang C, Guillot B, Cupissol B, Souteyrand P, Sassolas B, Cesarini IP, Thivolet I, Denoeux IP, Ortonne IP, Thomas T, Beylot C, Truchetet F, Lorette G, Chemaly C, Meynadier J, Amblard P, Thyss P, Avril MF, Prigent F, Bonerandi JJ. Randomised trial of interferon a-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. The Lancet, 1998; 351: 1905\u20131910","journal-title":"The Lancet"},{"key":"15_CR59","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.1995.13.11.2776","volume":"13","author":"ET Creagan","year":"1995","unstructured":"Creagan ET, Dalton RI, Ahmann DL, et al. Randomized surgical adjuvant clinical trial or recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13:2776\u20132783","journal-title":"J Clin Oncol"},{"key":"15_CR60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","volume":"14","author":"JM Kirkwood","year":"1996","unstructured":"Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH... Interferona2b adjuvant therapy of high-risk resected curaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7\u201317","journal-title":"J Clin Oncol"},{"key":"15_CR61","first-page":"410","volume":"14","author":"N Cascinelli","year":"1995","unstructured":"Cascinelli N: Evaluation of efficacy of adjuvant rIFNa 2 A in regional node metastases. Proc Am Soc Clin Oncol 14:410, 1995 (abstr)","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"S4","key":"15_CR62","first-page":"264","volume":"35","author":"U Kleeberg","year":"1999","unstructured":"Kleeberg U, Broecker EB, Chartier C, et al. EORTC 18871 adjuvant trial in high risk melanoma patients IFNa vs IFNgamma vs Iscador vs Observation. Eur J Cancer 1999: 35(S4):264(abstr)","journal-title":"Eur J Cancer"},{"key":"15_CR63","first-page":"2072","volume":"18","author":"JM Kirkwood","year":"1999","unstructured":"Kirkwood JM, Ibrahim J, Sondak V, et al: Preliminary analysis of the E1690\/S9111\/ C9190 Intergroup Postoperative Adjuvant Trial of High-and Low-Dose IFNa1pha2b (HDI and LDI) in High-Risk Primary or Lymph Node Metastatic Melanoma. Proc Am Soc Clin Oncol 1999; 18:2072 (abstr)","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Recent Results in Cancer Research","Lymphatic Metastasis and Sentinel Lymphonodectomy"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-57151-0_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T02:15:42Z","timestamp":1554171342000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-57151-0_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"ISBN":["9783642630705","9783642571510"],"references-count":63,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-57151-0_15","relation":{},"ISSN":["0080-0015"],"issn-type":[{"type":"print","value":"0080-0015"}],"subject":[],"published":{"date-parts":[[2000]]}}}